Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | BACE1 | P56817 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 2/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26149605 | 0.98 | BACE1 (0.67) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL4511163 | 0.92 | KDM4E (0.67) | LTA4HKDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL6583850 | 0.86 | KDM4E (0.61) | LTA4HKDM4ESMN1; SMN2ALDH1A1HTT | |
| SCHEMBL30798569 | 0.82 | KCNA5 (0.60) | KDM4ESMN1; SMN2ALDH1A1HTTLMNA | |
| SCHEMBL31475230 | 0.81 | KDM4E (0.82) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL8361480 | 0.81 | KDM4E (0.83) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL18483417 | 0.81 | LTA4H (0.66) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL264157 | 0.81 | LTA4H (0.81) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL7955174 | 0.81 | LTA4H (0.66) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 | |
| SCHEMBL265398 | 0.81 | KDM4E (0.82) | LTA4HKDM4ESMN1; SMN2ALDH1A1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3003314-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | KALA PHARMACEUTICALS INC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-8618132-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-1558578-B1 | NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-03-13 | — | — | EP | disclosed |
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-03-12 | — | — | US | disclosed |
| US-7452911-B2 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2008-11-18 | — | — | US | disclosed |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069282-A1 | ALKYNE COMPOUNDS WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | LTA4H 2076/4885KDM4E 1349/4885SMN1; SMN2 3224/4885 |
| US-20040209865-A1 | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MCHR2, NPY1R | LTA4H 2552/4885KDM4E 1450/4885SMN1; SMN2 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.